Safety, tolerability, and pharmacokinetics of TG-1000, a new molecular entity against influenza virus: first-in-human study

Background: The cap-snatching mechanism of influenza virus mRNA transcription is strongly suppressed by TG-1000, a prodrug rapidly metabolized into TG-0527, is a potent cap-dependent nucleic acid endonuclease inhibitor. Herein, we aimed to assess the safety, tolerability, and pharmacokinetics of TG-...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Su-Mei, Chang, Li-Wen, Tsai, Cheng-Yuan, Liu, Wan-Li, Li, Dai, Li, Shan-Shan, Li, Xiao-Min, Xu, Ping-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646326/
https://www.ncbi.nlm.nih.gov/pubmed/38027026
http://dx.doi.org/10.3389/fphar.2023.1272466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646326/
https://www.ncbi.nlm.nih.gov/pubmed/38027026
http://dx.doi.org/10.3389/fphar.2023.1272466

Ejemplares similares